Janux Therapeutics JANX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -1,143.1%+434pp | -1,576.7%-134pp | -1,442.9%+31,559pp | -33,002.1%-31,785pp | -1,216.6%-283pp | |
| Net margin | -833.6%+303pp | -1,136.3%-117pp | -1,019%+23,045pp | -24,064%-23,231pp | -832.7%-181pp | |
| EBITDA margin | -1,128.7%+428pp | -1,556.4%-134pp | -1,422.2%+31,106pp | -32,527.8%-31,333pp | -1,194.7%-281pp | |
| Free cash flow margin | -571.6%+261pp | -832.8%-119pp | -714%+13,114pp | -13,827.8%-13,329pp | -498.4%-81.2pp | |
| Returns | ||||||
| Return on equity | -11.7%-0.2pp | -11.5%+1.0pp | -12.5%+0.3pp | -12.8%-3.5pp | -9.3%+0.8pp | |
| Return on assets | -11%0.0pp | -11%+0.8pp | -11.8%+0.4pp | -12.3%-3.3pp | -8.9%+0.6pp | |
| Return on invested capital | -16.8%+3.7pp | -20.5%-2.5pp | -18%-0.2pp | -17.8%-1.9pp | -15.9%+4.6pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 17×-22.0× | 39×+3.2× | 35.9×-11.2× | 47×-11.4× | 58.5×-0.7× | |
| Quick ratio | 17×-22.0× | 39×+3.2× | 35.9×-11.2× | 47×-11.4× | 58.5×-0.7× | |
| Cash ratio | 0.9×-1.2× | 2.1×+0.4× | 1.7×-0.7× | 2.5×-1.8× | 4.2×-20.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $15.02-2.7% | $15.44-1.9% | $15.74-1.6% | $16.00-2.3% | $16.39-13.9% | |
| Valuation | ||||||
| Market capitalization | $889.15M-36.3% | $830.04M-43.5% | $1.47B+6.3% | $1.38B-13.4% | $1.6B-49.2% | |
| Enterprise value | $858.89M-36.2% | $799.84M-44.6% | $1.44B+6.8% | $1.35B-12.5% | $1.54B-43.5% | |
| Price / sales | 64.8×-84.8× | 83×-63.9× | 146.9×-3,001× | 3,147.5×+2,977× | 170.9×-126× | |
| Price / book | 0.9×-0.4× | 0.9×-0.6× | 1.5×+0.1× | 1.4×-0.2× | 1.6×-1.5× | |
| EV / sales | 62.5×-81.6× | 80×-64.3× | 144.3×-2,934× | 3,078.6×+2,913× | 165.5×-92.5× | |
| Free cash flow yield | -8.8%-5.5pp | -10%-5.2pp | -4.9%-0.5pp | -4.4%-1.5pp | -2.9%-1.5pp | |
| Earnings yield | -12.9%-7.3pp | -13.7%-6.8pp | -6.9%+0.7pp | -7.6%-2.8pp | -4.9%-2.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Janux Therapeutics's ratios come from?
- Every ratio is computed from Janux Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
